ArticleBMC cancer2024

Protocol for CHAMPION study: a prospective study of maximal-cytoreductive therapies for patients with de novo metastatic hormone-sensitive prostate cancer who achieve oligopersistent metastases during systemic treatment with apalutamide plus androgen deprivation therapy.

Beihe Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.